Fosun Pharma’s Subsidiary Gains Approval for New Drug

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Shanghai Fosun Pharmaceutical’s subsidiary, Hebei Wanbang Folon Pharmaceutical, has successfully had its drug registration application for Tao Hong Si Wu Granules accepted by the National Medical Products Administration. This innovative traditional Chinese medicine is designed to address symptoms related to blood deficiency and circulation, such as irregular menstruation and abdominal pain. The acceptance marks a significant step forward in expanding Fosun Pharma’s product offerings in the traditional medicine market.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.